Correlation Between X4 Pharmaceuticals and Zenas BioPharma,

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both X4 Pharmaceuticals and Zenas BioPharma, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining X4 Pharmaceuticals and Zenas BioPharma, into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between X4 Pharmaceuticals and Zenas BioPharma, Common, you can compare the effects of market volatilities on X4 Pharmaceuticals and Zenas BioPharma, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in X4 Pharmaceuticals with a short position of Zenas BioPharma,. Check out your portfolio center. Please also check ongoing floating volatility patterns of X4 Pharmaceuticals and Zenas BioPharma,.

Diversification Opportunities for X4 Pharmaceuticals and Zenas BioPharma,

-0.23
  Correlation Coefficient

Very good diversification

The 3 months correlation between XFOR and Zenas is -0.23. Overlapping area represents the amount of risk that can be diversified away by holding X4 Pharmaceuticals and Zenas BioPharma, Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Zenas BioPharma, Common and X4 Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on X4 Pharmaceuticals are associated (or correlated) with Zenas BioPharma,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Zenas BioPharma, Common has no effect on the direction of X4 Pharmaceuticals i.e., X4 Pharmaceuticals and Zenas BioPharma, go up and down completely randomly.

Pair Corralation between X4 Pharmaceuticals and Zenas BioPharma,

Given the investment horizon of 90 days X4 Pharmaceuticals is expected to generate 1.26 times more return on investment than Zenas BioPharma,. However, X4 Pharmaceuticals is 1.26 times more volatile than Zenas BioPharma, Common. It trades about 0.03 of its potential returns per unit of risk. Zenas BioPharma, Common is currently generating about -0.13 per unit of risk. If you would invest  119.00  in X4 Pharmaceuticals on October 5, 2024 and sell it today you would lose (44.00) from holding X4 Pharmaceuticals or give up 36.97% of portfolio value over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthInsignificant
Accuracy15.59%
ValuesDaily Returns

X4 Pharmaceuticals  vs.  Zenas BioPharma, Common

 Performance 
       Timeline  
X4 Pharmaceuticals 

Risk-Adjusted Performance

8 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in X4 Pharmaceuticals are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. Even with relatively unfluctuating basic indicators, X4 Pharmaceuticals reported solid returns over the last few months and may actually be approaching a breakup point.
Zenas BioPharma, Common 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Zenas BioPharma, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of inconsistent performance in the last few months, the Etf's forward indicators remain very healthy which may send shares a bit higher in February 2025. The recent disarray may also be a sign of long period up-swing for the ETF investors.

X4 Pharmaceuticals and Zenas BioPharma, Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with X4 Pharmaceuticals and Zenas BioPharma,

The main advantage of trading using opposite X4 Pharmaceuticals and Zenas BioPharma, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if X4 Pharmaceuticals position performs unexpectedly, Zenas BioPharma, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Zenas BioPharma, will offset losses from the drop in Zenas BioPharma,'s long position.
The idea behind X4 Pharmaceuticals and Zenas BioPharma, Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.

Other Complementary Tools

Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance